There are currently 817 clinical trials in Jacksonville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Florida, Mayo Clinic - Jacksonville, Mayo Clinic and Mayo Clinic Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Florida Memorial Hospital, Jacksonville, Florida
Conditions: Heart Failure
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
Recruiting
This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Amyotrophic Lateral Sclerosis
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Metastatic Castration-Resistant Prostate Cancer
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients with Inflammatory or Invasive Breast Cancer
Recruiting
This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to study in the laboratory may help doctors find better ways to treat and study inflammatory breast cancer in the future.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Baptist - MD Anderson Cancer Center, Jacksonville, Florida
Conditions: Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Second Primary Malignant Neoplasm
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Mayo Clinic - Jacksonville, Jacksonville, Florida
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia with an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients with Post-Menopausal Bleeding
Recruiting
This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions.
Gender:
FEMALE
Ages:
55 years and above
Trial Updated:
10/03/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Endometrial Carcinoma
Access BNP Clinical Enrollment Study
Recruiting
The goal of this study is to collect blood from subjects with a suspicion of either new onset or worsened heart failure to be used for testing studies for a new product to aid in the diagnosis of heart failure.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
10/01/2024
Locations: University of Florida College of Medicine - Jacksonville, Jacksonville, Florida
Conditions: Heart Failure
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: University of Florida - College of Medicine, Jacksonville, Florida +1 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases
Recruiting
The purpose of this study is to create a repository for cerebellar ataxia and nucleotide repeat diseases in order to fully investigate the genetic and phenotypic presentations of both.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Spinocerebellar Ataxias, Cerebellar Ataxia, Nucleotide Repeat Disease
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Clinical Trial Site, Jacksonville, Florida
Conditions: Generalized Myasthenia Gravis
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Recruiting
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Mayo Clinical Hospital Florida, Jacksonville, Florida
Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Preventing Alzheimer's With Cognitive Training
Recruiting
Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging and Alzheimer's disease or another type of dementia, and is indicative of higher risk for dementia. In addition to the obvious health and quality-of-life ramifications of dementia, there are high direct (e.g., subsidizing residentia... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/24/2024
Locations: University of Florida, Jacksonville, Florida +1 locations
Conditions: Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias